Phase 3 confirmatory trial of MAT2203 (administered with 5FC) with a control arm of IV amphotericin (also administered with 5-FC) as induction and then consolidation therapy in HIV patients with cryptococcal meningitis
Latest Information Update: 20 May 2022
At a glance
- Drugs Amphotericin B (Primary) ; Amphotericin B (Primary) ; Flucytosine
- Indications Cryptococcal meningitis
- Focus Adverse reactions
- Sponsors Matinas BioPharma
Most Recent Events
- 20 May 2022 New trial record
- 12 May 2022 According to a Matinas Biopharma media release, the company plans to meet with FDA in the third quarter of 2022 to finalize the trial design and anticipates that the pivotal Phase 3 registration trial will commence later in 2022, with the anticipated financial support of the National Institutes of Health.
- 12 May 2022 According to a Matinas Biopharma media release, data from this study will support single NDA filing for both induction and consolidation treatment with MAT2203 in patients with cryptococcal meningitis